MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cells take on tough leukemia in early trial
Disease control CompletedThis early-phase study tested a new treatment using lab-grown immune cells (iPSC NK cells) in 2 adults with hard-to-treat acute myeloid leukemia (AML) or signs of remaining disease after treatment. The main goal was to check safety and find the right dose. Researchers also looked…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Can zapping cancer spots delay lung cancer progression?
Disease control CompletedThis study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug aims to wipe out hidden leukemia cells before they return
Disease control CompletedThis study tested a drug called blinatumomab in 36 adults with B-cell acute lymphoblastic leukemia who were in remission but still had tiny amounts of cancer cells detectable (minimal residual disease). The goal was to see if the drug could clear those leftover cells and improve …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC